Cipla: Co. Enters Exclusive Licensing Deal With SBP Group For HER2 Bispecific ADC Rolditamig Deuderuxtecan (TQB2102); Deal Includes India, South Africa, And Five Other Emerging Markets; Cipla Will Manage Local Development And Sales.

 31 Aug 2026 03:45 PM

Cipla: Co. Enters Exclusive Licensing Deal With SBP Group For HER2 Bispecific ADC Rolditamig Deuderuxtecan (TQB2102); Deal Includes India, South Africa, And Five Other Emerging Markets; Cipla Will Manage Local Development And Sales.

Cipla: USFDA Classifies InvaGen Pharmaceuticals Inc.'s Unit 3 Inspection In New York As Voluntary Action Indicated (VAI)

 29 Aug 2026 09:21 AM

Cipla: USFDA Classifies InvaGen Pharmaceuticals Inc.'s Unit 3 Inspection In New York As Voluntary Action Indicated (VAI)

Cipla: Company Finalizes Restructuring With Aspergen Limited Taking Full Control Of Aspergen Inc.

 27 Aug 2026 08:21 PM

Cipla: Company Finalizes Restructuring With Aspergen Limited Taking Full Control Of Aspergen Inc.

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Pithampur received seven USFDA observations, but near- to medium-term earnings are unlikely to be affected due to key approvals being linked to Goa and US facilities, while eventual resolution would improve supply flexibility for respiratory products.

 26 Aug 2026 08:47 AM

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Pithampur received seven USFDA observations, but near- to medium-term earnings are unlikely to be affected due to key approvals being linked to Goa and US facilities, while eventual resolution would improve supply flexibility for respiratory products.

Cipla: Company Gets Form 483 With Seven Comments After USFDA Follow-Up Visit To Pithampur Facility

 25 Aug 2026 04:10 PM

Cipla: Company Gets Form 483 With Seven Comments After USFDA Follow-Up Visit To Pithampur Facility

Cipla: Co. Gets Form 483 With 7 Observations After USFDA Follow-Up Visit To Pithampur Facility.

 25 Aug 2026 04:12 PM

Cipla: Co. Gets Form 483 With 7 Observations After USFDA Follow-Up Visit To Pithampur Facility.

CIPLA: USFDA Inspects Unit IV Facility In Indore/Pithampur, Contributing 30% Of Company's Revenue - NDTV

 21 Aug 2026 01:20 PM

CIPLA: USFDA Inspects Unit IV Facility In Indore/Pithampur, Contributing 30% Of Company's Revenue - NDTV

CIPLA: Company Gets Approval Confirmation from USFDA for Invagen Pharmaceuticals' New York Manufacturing Facility.

 04 Aug 2026 09:03 AM

CIPLA: Company Gets Approval Confirmation from USFDA for Invagen Pharmaceuticals' New York Manufacturing Facility.

Cipla: Company Gets USFDA Approval for Generic Advair Diskus in All Three Strengths for Asthma and COPD Treatment.

 28 Jul 2026 07:57 AM

Cipla: Company Gets USFDA Approval for Generic Advair Diskus in All Three Strengths for Asthma and COPD Treatment.

Cipla: JPM on Cipla Maintains Overweight with Target Price of ₹1,600 as Q1 EBITDA margin missed estimates but FY27 margin guidance was retained, supported by a strong US launch pipeline and operating leverage.

 24 Jul 2026 09:02 AM

Cipla: JPM on Cipla Maintains Overweight with Target Price of ₹1,600 as Q1 EBITDA margin missed estimates but FY27 margin guidance was retained, supported by a strong US launch pipeline and operating leverage.

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Q1 was largely in line, FY27 margin guidance was retained, and robust India growth plus improving US launches support FY28 earnings upside.

 24 Jul 2026 09:02 AM

Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Q1 was largely in line, FY27 margin guidance was retained, and robust India growth plus improving US launches support FY28 earnings upside.

Cipla: Nomura on Cipla Maintains Buy with Target Price of ₹1,510 as Q1 EBITDA margin missed estimates, but retained FY27 margin guidance and high-value US launches are expected to drive margin recovery.

 24 Jul 2026 09:02 AM

Cipla: Nomura on Cipla Maintains Buy with Target Price of ₹1,510 as Q1 EBITDA margin missed estimates, but retained FY27 margin guidance and high-value US launches are expected to drive margin recovery.

Cipla: Upcoming US Pipeline Has Four Major Launches, Featuring Three Respiratory Products (One Being Generic Advair) And One Important Peptide Product. Two Respiratory Products Filed From US Facilities, And One From Goa Facility.

 24 Jul 2026 08:34 AM

Cipla: Upcoming US Pipeline Has Four Major Launches, Featuring Three Respiratory Products (One Being Generic Advair) And One Important Peptide Product. Two Respiratory Products Filed From US Facilities, And One From Goa Facility.

Cipla: North America Business Anticipates Ongoing Growth This Year Due To Upcoming Product Launches And Ongoing Sales Efforts, With A Target Of Reaching A $1 Billion Run Rate By FY27, Depending On New Product Approvals And Increased Ventolin Production.

 24 Jul 2026 08:34 AM

Cipla: North America Business Anticipates Ongoing Growth This Year Due To Upcoming Product Launches And Ongoing Sales Efforts, With A Target Of Reaching A $1 Billion Run Rate By FY27, Depending On New Product Approvals And Increased Ventolin Production.

Cipla: Company Achieves Record Q1 Revenue of INR 7,100 Crore for FY27, Demonstrating Strong Business Resilience. || FY27 EBITDA Margin Guidance Stays the Same at 18.5% to 20% Based on New Product Launches and Expected Margin Growth.

 24 Jul 2026 08:35 AM

Cipla: Company Achieves Record Q1 Revenue of INR 7,100 Crore for FY27, Demonstrating Strong Business Resilience. || FY27 EBITDA Margin Guidance Stays the Same at 18.5% to 20% Based on New Product Launches and Expected Margin Growth.

Cipla: Global CEO Gupta - Tariffs Is An Evolving Situation, We Will Monitor It || Tariffs Is An Evolving Situation, We Will Monitor It

 23 Jul 2026 03:18 PM

Cipla: Global CEO Gupta - Tariffs Is An Evolving Situation, We Will Monitor It || Tariffs Is An Evolving Situation, We Will Monitor It

Cipla: Expects Upcoming Reinspection Of Indore Facility; Four New Products In Development. - Concall Update

 23 Jul 2026 03:18 PM

Cipla: Expects Upcoming Reinspection Of Indore Facility; Four New Products In Development. - Concall Update

Cipla: Global CEO - Have Experience In Diversifying Manufacturing, We Will Be Able To Adapt

 23 Jul 2026 03:19 PM

Cipla: Global CEO - Have Experience In Diversifying Manufacturing, We Will Be Able To Adapt

Cipla: Plans Exciting Product Launches And Looks To Improve Distribution Network. - Concall Update

 23 Jul 2026 03:19 PM

Cipla: Plans Exciting Product Launches And Looks To Improve Distribution Network. - Concall Update

Cipla: Co. Retains 18-20% EBITDA Margin Forecast For FY27 - Concall Update

 23 Jul 2026 03:21 PM

Cipla: Co. Retains 18-20% EBITDA Margin Forecast For FY27 - Concall Update